Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease

Table 4

Correlation between increase of Hb concentration expressed as absolute values (Δ) or as percentages (%) and change of evaluated biomarkers expressed as absolute values (Δ) or as percentages (%) in CKD patients.

Biomarkers (Δ) after-before treatment	Hb (Δ) after-before treatment	Biomarkers (%); (after-before)/before treatment  ×  100	Hb (%); (after-before)/before treatment  ×  100
IL-1β	−0.511	IL-1β	−0.484
TNF-RI	−0.061	TNF-RI	−0.081
TNF-RII	−0.250	TNF-RII	−0.276
sFasL	−0.070	sFasL	−0.088
sFas	−0.096	sFas	−0.093
sE-selectin	−0.128	sE-selectin	−0.105
sICAM-1	0.144	sICAM-1	0.125
TIMP-1	0.040	TIMP-1	0.066
sVCAM-1	−0.074	sVCAM-1	0.013
MMP-9	0.094	MMP-9	0.055
TGF-β1	−0.124	TGF-β1	−0.098

Spearman correlation coefficient values, .
Hb = hemoglobin, CKD = chronic kidney disease, IL-1β = interleukin 1β, TNF-RI = soluble tumor necrosis factor receptor I, TNF-RII = soluble tumor necrosis factor receptor II, sFasL = soluble Fas ligand, sFas = soluble Fas, sICAM-1 = soluble intercellular adhesion molecule-1, TIMP-1 = tissue inhibitor of metalloproteinase-1, sVCAM-1 = soluble human vascular cell adhesion molecule-1, MMP-9 = metalloproteinase-9, and TGF-β1 = transforming growth factor-beta 1.